Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study Vicente Pallarés-Carratalá; Antonio Ruiz-García; Adalberto Serrano-Cumplido; Antonio Segura Fragoso; Verónica Fernández-Pascual; Beatriz Sánchez-Sánchez; María Inmaculada Cervera-Pérez; Francisco Javier Alonso-Moreno; Ezequiel Arranz-Martínez; Alfonso Barquilla-García; Daniel Rey-Aldana; José Polo García; Sergio Cinza-Sanjurjo;

Prevalence rates of overweight and obesity and their associations with cardiometabolic and renal factors. SIMETAP-OB study Antonio Ruiz-García; Ezequiel Arranz-Martínez; Luis Enrique Morales-Cobos; Juan Carlos García-Álvarez; Nerea Iturmendi-Martínez; Montserrat Rivera-Teijido;

The benefits of measuring the size and number of lipoprotein particles for cardiovascular risk prediction: A systematic review and meta-analysis Jose A. Quesada; Vicente Bertomeu-González; Domingo Orozco-Beltrán; Alberto Cordero; Vicente F. Gil-Guillén; Adriana López-Pineda; Rauf Nouni-García; Concepción Carratalá-Munuera;